MONASH UNIVERSITY

A retrospective analysis of 6,217 CLL patients in Australia found that regular immunoglobulin replacement therapy was not associated with reduced risk of serious infections requiring hospitalization.

Eight healthy babies were born in Britain using an experimental technique that combines DNA from three people to prevent mothers from passing devastating mitochondrial diseases to their children.

A large observational study of 13,811 women with early-stage breast cancer found that aprepitant, a commonly prescribed anti-nausea medication, was associated with an 11% lower risk of cancer recurrence and 17% lower risk of breast cancer-related death.

The phase 3 BM12 CAST trial demonstrated that cyclophosphamide plus cyclosporin significantly improved graft-versus-host disease-free relapse-free survival compared to standard cyclosporin/methotrexate prophylaxis in blood cancer patients.

Immuron is on track to exceed A$7 million in sales this financial year, representing a significant increase from the previous year's A$4.9 million.

Melbourne-based PolyActiva raised $40 million in Series C funding, including $27 million from Australia's National Reconstruction Fund, to advance its biodegradable glaucoma treatment implant.

A six-month clinical trial found that metformin, a common diabetes medication, significantly reduced knee osteoarthritis pain in overweight patients by 31.3 points compared to 18.9 points in the placebo group.

New research reveals individuals with LDL cholesterol below 70 mg/dl demonstrated a 26% lower risk of dementia and 28% lower risk of Alzheimer's compared to those with levels above 130 mg/dl.

The British Thoracic Society's analysis of the UK Idiopathic Pulmonary Fibrosis Registry provides the first comprehensive long-term data on over 5,000 IPF cases across 64 UK hospitals.

• An Australian man in his 40s lived for 100 days with the BiVACOR Total Artificial Heart while awaiting a donor transplant, marking the longest period anyone has survived with this technology. • The patient became the first person worldwide to be discharged from hospital with the artificial heart in February, demonstrating the device's potential as a long-term solution for severe heart failure. • BiVACOR is currently raising $100 million to fund further clinical trials, with experts predicting artificial hearts could become a viable alternative for patients unable to wait for donor hearts within the next decade.